» Articles » PMID: 38997794

Cellular Senescence and Metabolic reprogramming: Unraveling the Intricate Crosstalk in the Immunosuppressive Tumor Microenvironment

Overview
Publisher Wiley
Specialty Oncology
Date 2024 Jul 12
PMID 38997794
Authors
Affiliations
Soon will be listed here.
Abstract

The intrinsic oncogenic mechanisms and properties of the tumor microenvironment (TME) have been extensively investigated. Primary features of the TME include metabolic reprogramming, hypoxia, chronic inflammation, and tumor immunosuppression. Previous studies suggest that senescence-associated secretory phenotypes that mediate intercellular information exchange play a role in the dynamic evolution of the TME. Specifically, hypoxic adaptation, metabolic dysregulation, and phenotypic shifts in immune cells regulated by cellular senescence synergistically contribute to the development of an immunosuppressive microenvironment and chronic inflammation, thereby promoting the progression of tumor events. This review provides a comprehensive summary of the processes by which cellular senescence regulates the dynamic evolution of the tumor-adapted TME, with focus on the complex mechanisms underlying the relationship between senescence and changes in the biological functions of tumor cells. The available findings suggest that components of the TME collectively contribute to the progression of tumor events. The potential applications and challenges of targeted cellular senescence-based and combination therapies in clinical settings are further discussed within the context of advancing cellular senescence-related research.

Citing Articles

Untangling the Role of MYC in Sarcomas and Its Potential as a Promising Therapeutic Target.

Sias F, Zoroddu S, Migheli R, Bagella L Int J Mol Sci. 2025; 26(5).

PMID: 40076599 PMC: 11900228. DOI: 10.3390/ijms26051973.


NK cells: shielding senescence homeostasis in the decidua during early pregnancy.

Zheng Z, Shi J, Wang L, Li M Semin Immunopathol. 2025; 47(1):22.

PMID: 40067562 DOI: 10.1007/s00281-025-01048-7.


Impact of glycolysis enzymes and metabolites in regulating DNA damage repair in tumorigenesis and therapy.

Sun F, Li W, Du R, Liu M, Cheng Y, Ma J Cell Commun Signal. 2025; 23(1):44.

PMID: 39849559 PMC: 11760674. DOI: 10.1186/s12964-025-02047-9.


Single-cell profiling of SLC family transporters: uncovering the role of SLC7A1 in osteosarcoma.

Liao Y, Chen J, Yao H, Zheng T, Tu J, Chen W J Transl Med. 2025; 23(1):103.

PMID: 39844299 PMC: 11752724. DOI: 10.1186/s12967-025-06086-1.


From Bench to Bedside: Translating Cellular Rejuvenation Therapies into Clinical Applications.

Saliev T, Singh P Cells. 2025; 13(24.

PMID: 39768144 PMC: 11674796. DOI: 10.3390/cells13242052.


References
1.
Johnson N, Conneely K . The role of DNA methylation and hydroxymethylation in immunosenescence. Ageing Res Rev. 2019; 51:11-23. DOI: 10.1016/j.arr.2019.01.011. View

2.
Yang S, Hwang S, Kim M, Seo S, Lee J, Jeong S . Mitochondrial glutamine metabolism via GOT2 supports pancreatic cancer growth through senescence inhibition. Cell Death Dis. 2018; 9(2):55. PMC: 5833441. DOI: 10.1038/s41419-017-0089-1. View

3.
Ghosh A, Michels J, Mezzadra R, Venkatesh D, Dong L, Gomez R . Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade. J Clin Invest. 2022; 132(18). PMC: 9479603. DOI: 10.1172/JCI148141. View

4.
Petroni G, Buque A, Coussens L, Galluzzi L . Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. Nat Rev Drug Discov. 2022; 21(6):440-462. DOI: 10.1038/s41573-022-00415-5. View

5.
Nicolas-Boluda A, Vaquero J, Vimeux L, Guilbert T, Barrin S, Kantari-Mimoun C . Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment. Elife. 2021; 10. PMC: 8203293. DOI: 10.7554/eLife.58688. View